World Alzheimer's Day 2021: The Power of Knowledge

World Alzheimer's Day is an international campaign organised by Alzheimer's Disease International to raise awareness and highlight issues faced by people affected by dementia. It takes place every year on September 21st and is the focus of World Alzheimer's Month.

Dementia is one of the biggest challenges we face, with nearly 50 million people living with dementia worldwide. Yet 2 out of every 3 people globally believe there is little or no understanding of dementia in their countries.The impact of World Alzheimer's Month is growing, but the stigmatisation and misinformation that surrounds dementia remains a global problem. To tackle this challenge, we need to collaborate and share best practice with one another.

In support of this year’s theme – ‘Know dementia, know Alzheimer's’ - Elsevier presents a curated, open access collection of over 70 journal articles and book chapters focused on shining a light on the warning signs of dementia and the importance of a timely diagnosis.


Molecular Mechanisms of Dementia, April 2019, Pages 73-112

This book chapter advances SDGs 3 and 17 by reviewing the neurochemical aspects of Alzheimer’s type of Dementia.

Evidence-informed Approaches for Managing Dementia Transitions: Riding the Waves, Volume , 4 February 2020

This book chapter advances SDGs 3 and 17 by describing the prevalence of dementia in hospitalized patients, reasons for hospitalizations, and risks to older people with dementia in hospitals. Strategies for optimizing outcomes and models of care that are designed to improve care of persons with dementia and their care partners are described to assist healthcare team members working with this unique population.

Neuroprotection in Autism, Schizophrenia and Alzheimer's disease, Volume , 16 October 2019

This book chapter advances SDGs 3 and 17 by reviewing a new promising neuroprotective approach to treating AZ, Tau-based therapies including tau-kinase inhibitors to acetylation inhibitors, microtubule stabilizers, aggregation inhibitors, monoclonal anti-tau antibodies or active tau vaccines. Special emphasis has been placed on the most promising therapeutic agents that have reached clinical trials.

Evidence-informed Approaches for Managing Dementia Transitions: Riding the Waves, Volume , 4 February 2020

This book chapter advances SDGs 3 and 17 by introducing aspects of the lived experience, management, and epidemiology of dementia and some of the significant transitions that people with the disease and their caregivers frequently encounter.
Elsevier, Archives of Gerontology and Geriatrics, Volume 86, January - February 2020
We investigated emotional regulation of autobiographical memories in Alzheimer's disease (AD). AD patients and control participants were asked to retrieve memories in response to “happy” and “sad” cues. Participants were also asked to rate the emotional valence of memories at retrieval as well as at the moment the events were encoded. Results showed that both control participants and AD patients rated memories cued by “happy” as more positive when retrieved than when encoded.
Elsevier, Pharmacology Biochemistry and Behavior, Volume 184, September 2019
Background: Alzheimer's disease (AD) is the most common neurodegenerative disease causing dementia in the elderly population. Due to the fact that there is still no cure for Alzheimer's dementia and available treatment strategies bring only symptomatic benefits, there is a pressing demand for other effective strategies such as diet. Since the inflammation hypothesis gained considerable significance in the AD pathogenesis, elucidating the modulatory role of dietary factors on inflammation may help to prevent, delay the onset and slow the progression of AD.
Elsevier, Journal of Steroid Biochemistry and Molecular Biology, Volume 190, June 2019
Alzheimer's disease (AD) is the most common form of dementia and it is characterized by the deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain. However, the complete pathogenesis of the disease is still unknown. High level of serum cholesterol has been found to positively correlate with an increased risk of dementia and some studies have reported a decreased prevalence of AD in patients taking cholesterol-lowering drugs.
Elsevier, Cortex, Volume 115, June 2019
Background: Memory for music has attracted much recent interest in Alzheimer's disease but the underlying brain mechanisms have not been defined in patients directly. Here we addressed this issue in an Alzheimer's disease cohort using activation fMRI of two core musical memory systems. Methods: We studied 34 patients with younger onset Alzheimer's disease led either by episodic memory decline (typical Alzheimer's disease)or by visuospatial impairment (posterior cortical atrophy)in relation to 19 age-matched healthy individuals.
Elsevier, Neurobiology of Stress, Volume 10, February 2019
The Alzheimer's disease (AD) was discovered and the pathological hallmarks were revealed more than a century ago. Subsequently, many remarkable discoveries and breakthroughs provided us with mechanistic insights into the pathogenesis of AD. The identification of the molecular underpinning of the disease not only provided the framework of AD pathogenesis but also targets for therapeutic inventions. Despite all the initial successes, no effective treatment for AD has emerged yet as all the late stage of clinical trials have failed.
Elsevier, Neurobiology of Stress, Volume 9, November 2018
Exercise has been shown to reduce the risk of developing Mild Cognitive Impairment and Alzheimer's disease as well as to improve cognition in healthy and cognitively impaired individuals. However, the mechanisms of these benefits are not well understood. The stress hypothesis suggests that the cognitive benefits attributed to exercise may partially be mediated by changes in the cortisol secretion pattern.